ERR4976610
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 102
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.410
- ANGIOGENESIS+0.260
- SPERMATOGENESIS+0.240
- MYOGENESIS+0.190
- KRAS_SIGNALING_DN+0.160
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.130
- G2M_CHECKPOINT+0.090
- COAGULATION+0.050
- UV_RESPONSE_DN+0.050
- BILE_ACID_METABOLISM+0.040
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.440
- MYC_TARGETS_V2-0.430
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.430
- DNA_REPAIR-0.340
- OXIDATIVE_PHOSPHORYLATION-0.330
- TNFA_SIGNALING_VIA_NFKB-0.330
- INFLAMMATORY_RESPONSE-0.320
- NOTCH_SIGNALING-0.310
- CHOLESTEROL_HOMEOSTASIS-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12696783 | — | — | 0.848 |
| 2 | SRR12202443 | — | — | 0.835 |
| 3 | SRR1516070 | — | — | 0.831 |
| 4 | TCGA-CN-A49A-01A-11R-A24H-07 | — | — | 0.830 |
| 5 | SRR12202470 | — | — | 0.830 |
| 6 | TCGA-WA-A7H4-01A-21R-A34R-07 | — | — | 0.829 |
| 7 | MNG35 | — | — | 0.829 |
| 8 | 266352 | EPN | EPN Tumor | 0.824 |
| 9 | MNG1289 | — | — | 0.819 |
| 10 | MNG284 | — | — | 0.813 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.410 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.260 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.130 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.090 | Inavolisib | — uncovered |
| COAGULATION | 0.050 | Binimetinib | — uncovered |
| UV_RESPONSE_DN | 0.050 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |